MedPharm Opens New Facility in UK
MedPharm opens a new topical and transdermal formulation-development services facility in Guildford, United Kingdom.
MedPharm, a speciality pharmaceutical company providing topical and transdermal formulation development services, has opened a new £.5 million ($680 thousand) GMP facility in Guildford, United Kingdom.
The investment adds a microbiology laboratory, cleanroom suites, an ICH stability testing area, and quality-control and performance-testing laboratories to support Phase I and II clinical manufacture. The facility also allows for the manufacture of highly potent compounds up to OEB level 4 with a manufacturing batch scale of up to 50 kg and primary packaging, labeling, and randomization services.
Source: MedPharm,
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
